NCT02951351View on ClinicalTrials.gov

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

February 1, 2018

Study Completion Date

February 28, 2018

Conditions
Age-related Macular DegenerationDiabetic Macular EdemaInjection SiteInjection Site InfectionPain, Postoperative
Interventions
DRUG

Proparacaine

Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.

PROCEDURE

Conjunctival culture

Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.

Trial Locations (1)

55901

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

VitreoRetinal Surgery, PA

OTHER

collaborator

Research to Prevent Blindness

OTHER

lead

Mayo Clinic

OTHER